Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Chardan Capital Downgrades Evelo Biosciences to Neutral, Announces $2.5 Price Target

Chardan Capital analyst Keay Nakae downgrades Evelo Biosciences (NASDAQ:EVLO) from Buy to Neutral and announces $2.5 price target.
byBenzinga Newsdesk
November 16, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Chardan Capital analyst Keay Nakae downgrades Evelo Biosciences (NASDAQ:EVLO) from Buy to Neutral and announces $2.5 price target.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Analyst Ratings for Bloom Energy

By Benzinga Insights
July 8, 2:10 PM
Over the past 3 months, 4 analysts have published their opinion on Bloom Energy (NYSE:BE) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

BE